Effects of Arginase Inhibition in Hypertensive Hyperthyroid Rats

American Journal of Hypertension

Volumn 28, Issue 12, 2015, Pages 1464-1472

  Rodríguez Gómez, Isabel ^a,b   Manuel Moreno, Juan ^a,c   Jimenez, Rosario ^a,d   Quesada, Andrés ^a,e   Montoro Molina, Sebastian ^a,e   Vargas Tendero, Pablo ^a,b   Wangensteen, Rosemary ^a,e   Vargas, Félix ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d Facultad de Farmacia   (Spain)

^e UNIVERSITY OF JAÉN   (Spain)

Author keywords

arginase activity; blood pressure; hypertension; hyperthyroidism; nor NOHA; oxidative stress

Indexed keywords

ARGINASE; ARGINASE 1; ARGINASE 2; HYDROLASE INHIBITOR; ISOPROSTANE DERIVATIVE; N [OMEGA]HYDROXY NOR LEVO ARGININE; POTASSIUM; SODIUM; THYROXINE; UNCLASSIFIED DRUG; UREA; ARGININE; N(OMEGA)-HYDROXYNORARGININE; NITRIC OXIDE; THYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; BRAIN STEM; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIURESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FLUID INTAKE; FOOD INTAKE; GLOMERULUS FILTRATION RATE; HEART; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPERTENSION; HYPERTHYROIDISM; KALIURESIS; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY HYPERTROPHY; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MICTURITION; NATRIURESIS; NONHUMAN; OXIDATIVE STRESS; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SODIUM BALANCE; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; UREA BLOOD LEVEL; UREA CYCLE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; KIDNEY CIRCULATION; METABOLISM; PRECLINICAL STUDY; RANDOMIZATION; URINE; WISTAR RAT;

ANIMALS; ARGINASE; ARGININE; BLOOD PRESSURE; BRAIN STEM; DRUG EVALUATION, PRECLINICAL; HEART RATE; HYPERTENSION; HYPERTHYROIDISM; ISOPROSTANES; MALE; NITRIC OXIDE; RANDOM ALLOCATION; RATS, WISTAR; RENAL CIRCULATION; THYROID HORMONES;

EID: 84949987057     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpv049     Document Type: Article

References (38)

1. Meijer AJ, Lamers WH, Chamuleau RA. Nitrogen metabolism and ornithine cycle function. Physiol Rev 1990; 70:701-748.
2. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336(Pt 1):1-17.
3. Jenkinson CP, Grody WW, Cederbaum SD. Comparative properties of arginases. Comp Biochem Physiol 1996; 114B: 107-132.
4. Morris, SM Jr. Arginine synthesis, metabolism, and transport: regulators of nitric oxide synthesis. In Laskin JD, Laskin DL (eds), Cellular and Molecular Biology of Nitric Oxide. Dekker: New York, 1999, pp. 57-85.
5. Morris SM Jr, Bhamidipati D, Kepka-Lenhart D. Human type II arginase: sequence analysis and tissue-specific expression. Gene 1997; 193:157-161.
6. Shi O, Kepka-Lenhart D, Morris SM Jr, O'Brien WE. Structure of the murine arginase II gene. Mamm Genome 1998; 9:822-824.
7. Buga GM, Singh R, Pervin S, Rogers NE, Schmitz DA, Jenkinson CP, Cederbaum SD, Ignarro LJ. Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 1996; 271:H1988-H1998.
8. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA 2001; 98:4202-4208.
9. Zhang C, Hein TW, Wang W, Chang CI, Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxidemediated vasodilatory function. FASEB J 2001; 15:1264-1266.
10. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, Humphrey JD, Kuo L. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles. Hypertension 2004; 44:935-943.
11. Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001; 280:E75-E82.
12. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 287:L60-L68.
13. Topal G, Topal JL, Brunet A, Walch L, Boucher JL, David-Dufilho M. Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells. J Pharmacol Exp Ther 2006; 318:1368-1374.
14. Bagnost T, Berthelot A, Bouhaddi M, Laurant P, Andre C, Guillaume Y, Demougeot C. Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 2008; 26:1110-1118.
15. Rodriguez S, Richert L, Berthelot A. Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens 2000; 22:75-85.
16. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase inhibition restores arteriolar endothelial function in Dahl rats with saltinduced hypertension. Am J Physiol Regul Integr Comp Physiol 2005; 288:R1057-R1062.
17. Demougeot C, Prigent-Tessier A, Marie C, Berthelot A. Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 2005; 23:971-978.
18. Demougeot C, Prigent-Tessier A, Bagnost T, Andre C, Guillaume Y, Bouhaddi M, Marie C, Berthelot A. Time course of vascular arginase expression and activity in spontaneously hypertensive rats. Life Sci 2007; 80:1128-1134.
19. Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990; 88:631-637.
20. Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, Alvarez-Guerra M, Garcia-Estan J. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 2006; 154:197-212.
21. Moreno JM, Rodriguez Gomez I, Wangensteen R, Osuna A, Bueno P, Vargas F. Cardiac and renal antioxidant enzymes and effects of tempol in hyperthyroid rats. Am J Physiol Endocrinol Metab 2005; 289:E776-E783.
22. Garcia-Estan J, Atucha NM, Quesada T, Vargas F. Involvement of reninangiotensin system in the reduced pressure natriuresis response of hyperthyroid rats. Am J Physiol 1995; 268:E897-E901.
23. Rodriguez-Gomez I, Wangensteen R, Moreno JM, Chamorro V, Osuna A, Vargas F. Effects of chronic inhibition of inducible nitric oxide synthase in hyperthyroid rats. Am J Physiol Endocrinol Metab 2005; 288:E1252-E1257.
24. Quesada A, Sainz J, Wangensteen R, Rodriguez-Gomez I, Vargas F, Osuna A. Nitric oxide synthase activity in hyperthyroid and hypothyroid rats. Eur J Endocrinol 2002; 147:117-122.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
26. Granger DL, Taintor RR, Boockvar KS, Hibbs JB. Measurement of nitrate and nitrite in biochemical samples using nitrate reductase and Griess reaction. Methods Enzymol 1996; 268: 142-151.
27. Calamandrei G, Venerosi AP, Valanzano A, de Berardinis MA, Greco A, Puopolo M, Minghetti L. Increased brain levels of F2-isoprostane are an early marker of behavioral sequels in a rat model of global perinatal asphyxia. Pediatr Res 2004; 55:85-92.
28. Corraliza IM, Campo ML, Soler G, Modolell M. Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994; 174:231-235.
29. Moreno JM, Rodriguez Gomez I, Wangensteen R, Alvarez-Guerra M, Luna JD, Garcia-Estan J, Vargas F. Tempol Improves Renal Hemodynamics and Pressure-Natriuresis in Hyperthyroid Rats. Am J Physiol 2008; 294: R867-R873.
30. Perez-Abud R, Rodriguez-Gomez I, Villarejo AB, Moreno JM, Wangensteen R, Tassi M, O'Valle F, Osuna A, Vargas F. Salt sensitivity in experimental thyroid disorders in rats. Am J Physiol Endocrinol Metab 2011; 301:E281-E287.
31. Larsen PR, Davis TF, Hay ID. The thyroid gland. In Wilson JD, Foster DW, Kronenberg HK, Larsen PR (eds), Williams Textbook of Endocrinology, 6th edn. Saunders: London: 1998, pp. 389-515.
32. Roberts LJ II, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta 1997; 1345:121-135.
33. Cherla G, Jaimes EA. Role of L-arginine in the pathogenesis and treatment of renal disease. J Nutr 2004; 134:2801S-2806S.
34. Campese VM, Ye S, Zhong H, Yanamadala V, Ye Z, Chiu J. Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 2004; 287:H695-H703.
35. Rodriguez-Gomez I, Baca Y, Moreno JM, Wangensteen R, Perez-Abud R, Paya JA, O'Valle F, Vargas F. Role of sympathetic tone in BSO-induced hypertension in mice. Am J Hypertens 2010; 23:882-888.
36. Morgan T, Aubert JF, Brunner H. Interaction between sodium intake, angiotensin II, and blood pressure as a cause of cardiac hypertrophy. Am J Hypertens 2001; 14:914-920.
37. Ford HC, Lim WC, Chisnall WN, Pearce JM. Renal function and electrolyte levels in hyperthyroidism: urinary protein excretion and the plasma concentrations of urea, creatinine, uric acid, hydrogen ion and electrolytes. Clin Endocrinol (Oxf) 1989; 30:293-301.
38. Iyer RK, Yoo PK, Kern RM, Rozengurt N, Tsoa R, O'Brien WE, Yu H, Grody WW, Cederbaum SD. Mouse model for human arginase deficiency. Mol Cell Biol 2002; 22:4491-4498